Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome

摘要: Continuous positive airway pressure (CPAP) is the treatment of choice for sleep apnoea/hypopnoea syndrome (SAHS); it usually given with aim improving daytime cognitive function, mood, and sleepiness. However, its efficacy has not been validated by controlled trials. We have carried out a randomised, placebo-controlled, crossover study objective sleepiness, symptoms, mood in consecutive series 32 SAHS patients median apnoea plus hypopnoea frequency 28 (range 7-129) per hour slept. Patients were treated 4 weeks each CPAP an oral placebo, which they told might improve upper muscle function during sleep. Assessments on last day included multiple latency test tests symptom scores, profiles, performance. The had significantly less sleepiness than placebo period (mean 7.2 [SE 0.7] vs 6.1 [0.7] min, p = 0.03). There also improvements ratings (2.1 [0.2] 4.3 [0.3], < 0.001), (p 0.05 several measures), performance, showed improved vigilance (obstacles hit Steer Clear "driving" 76 [5] 81 [6], 0.01), mental flexibility (trail-making B time 66 75 s, 0.05), attention 0.05). Objectively monitored use averaged only 3.4 (0.4) hours night, but this provides evidence performance even at low level compliance.